Biotech Values

[DewDiligence]

After the sharp drop, VRTX now appears to be reasonably priced, IMO.

>Do you think they'll need full 48 week data now before filing, instead of just the 24 weeks?<

The control arms in the phase-2 studies are 48 weeks, and these data (which have not yet been reported) are relevant for obvious reasons.

We don’t yet know the design of the phase-3 Telaprevir studies, but it’s reasonable to assume that there will again be 48-week control arms.

In short, the Telaprevir NDA submission is still pretty far off.